Combined medicine for treating cancer

Through the combined use of beta elene with pemetrexed disodium, zebutinib or venetoc, the toxic side effects and drug resistance of existing chemotherapy drugs in the treatment of cancer, providing a stronger Tumor cell inhibition effect and therapeutic selectivity are suitable for many types of cancer.

CN119055656APending Publication Date: 2024-12-03SICHUAN HONGHE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310924991.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2023-07-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing chemotherapeutic drugs have problems with large systemic toxic side effects, strong drug resistance and poor selectivity when treating cancer, and lack effective combination dosage forms and administration methods to meet the treatment needs of cancer patients.

Method used

Develop a combination drug containing beta elene and a second drug (pemetrexed disodium, zebutinib or venetoc) to improve the effect on tumor cell growth inhibitory activity by different Molar ratio combinations provide a single compound preparation or a combination of two separate preparations to prepare into a variety of pharmaceutical compositions suitable for different types of cancer treatment.

Benefits of technology

Through the combined use of beta elene and pemetrexed disodium, zebutinib or venetoc, the growth inhibition effect on tumor cells is significantly improved, and systemic toxic side effects are reduced, and a stronger therapeutic option is provided Sex and drug resistance are suitable for a variety of cancers, including leukemia, lung cancer, breast cancer, etc.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a combined medicine for treating cancer, the combined medicine comprises beta elemene and a second medicine, and the second medicine is selected from pemetrexed disodium, zerbutinib and vionetog, and the second medicine comprises beta elemene, beta elemene, beta elemene, beta elemene, beta elemene, beta elemene, beta elemene, beta elemene, beta elemene and beta elemene.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a combination drug for treating cancer with beta-elemene, and relates to the field of medicine. Background Art

[0002] Cancer is currently a major disease that threatens human health. In my country, approximately 1.8 million patients are diagnosed with the disease each year, and the incidence rate is increasing year by year. Currently, cancer treatment mainly relies on surgery, chemotherapy, and radiotherapy. However, a large number of chemotherapy drugs currently used in clinical practice still have problems such as large systemic toxicity and side effects, drug resistance, and poor selection. In recent years, a large number of clinical and experimental studies have shown that traditional Chinese medicine and combined drug therapy have special effects in the prevention, treatment, and rehabilitation of tumors, and have gradually become the focus of attention.

[0003] β-elemene is the main component of zedoary turmeric oil and citronella oil, and is now widely used to treat cancer. It has been reported that elemene can be used in combination with anti-tumor drugs such as gefitinib and celecoxib to enhance the inhibitory activity of the above substances on tumor cell growth.

[0004] In order to meet the treatment needs of cancer patients as quickly as possible, it is urgent to develop more clinically valuable combination drug formulations and administration methods. Summary of the invention

[0005] The present invention provides a combination drug for treating cancer, wherein the combination drug comprises β-elemene and a second drug, wherein the combination drug is a single compound preparation or a combination of two separate preparations, and the second drug is selected from pemetrexed disodium, zanubrutinib and venetoclax.

[0006] Further, the second drug is pemetrexed disodium, and the molar ratio of pemetrexed disodium to β-elemene is 1:165-1:82, preferably 1:165-1:41, preferably 1:165-1:30, preferably 1:165-1:20, 1:165-1:10, preferably 1:165-1:5, preferably 1:165-1:3, preferably 1:165-1:2, preferably 1:165-1:1, preferably 1:165-1:0.5, preferably 1:165-1:0.3, preferably 1:165-1:0.1, preferably 1:150-1 :20, preferably 1:150-1:30, preferably 1:150-1:41, preferably 1:150-1:82, preferably 1:140-1:20, preferably 1:140-1:30, preferably 1:140-1:41, preferably 1:140-1:82, preferably 1:120-1:20, preferably 1:120-1:30, preferably 1:120-1:41, preferably 1:120-1:82, preferably 1:100-1:20, preferably 1:100-1:30, preferably 1:100-1:41, preferably 1:100-1:82,

[0007] Preferred 1:82-1:20, preferred 1:82-1:30, preferably 1:82-1:41, preferably 1:41-1:20, preferably 1:41-1:30.

[0008] Further, the molar ratio of pemetrexed disodium to β-elemene is 1:165, 1:160, 1:155, 1:150, 1:145, 1:140, 1:135, 1:130, 1:125, 1:120, 1:115, 1:110, 1:105, 1:100, 1:95, 1:90, 1:85, 1:82, 1:80, 1:75, 1:70, 1:65, 1:60, 1:55, 1:50, 1:45, 1:41, 1:35, 1:30, 1:25, 1:20, 1:15, 1:10, 1:5, 1:3, 1:2, 1:1, 1:0.5, 1:0.3, 1:0.2, and 1:0.1.

[0009] Further, the second drug is zanubrutinib, and the molar ratio of zanubrutinib to β-elemene is 1:1041666-1:50000, preferably 1:1041666-1:100000, preferably 1:1041666-1:130208, preferably 1:1041666-1:260416, preferably 1:1041666-1:502833, preferably It is 1:502833-1:50000, preferably 1:502833-1:100000, preferably 1:502833-1:130208, preferably 1:502833-1:260416, preferably 1:260416-1:50000, preferably 1:260416-1:100000, preferably 1:260416-1:130208.

[0010] Furthermore, the molar ratio of zanubrutinib to β-elemene is 1:1041666, 1:502833, 1:260416, 1:130208, 1:100000, and 1:50000.

[0011] Further, the second drug is venedoc, and the molar ratio of venedoc to β-elemene is 1:3333-1:0.3, preferably 1:3333-1:3, preferably 1:3333-1:17, preferably 1:3333-1:33, preferably 1:3333-1:104, preferably 1:3333-1:208, preferably 1:3333-1:417, preferably 1:3333-1:833, preferably 1:3333-1:1667, preferably 1:3333-1:2000, preferably 1:3333-1:2333, preferably 1:3333-1:2667, preferably 1:3333-1:3000, preferably 1:3000-1:0.3 ... 1:3000-1:3, preferably 1:3000-1:17, preferably 1:3000-1:33, preferably 1:3000-1:104, preferably 1:3000-1:208, preferably 1:3000-1:417, preferably 1:3000-1:833, preferably 1:3000-1:1667, preferably 1:3000-1:2000, preferably 1:3000-1:2333, preferably 1:3000-1:2667, preferably 1:2667-1:0.3, preferably 1:2667-1:3, preferably 1:2667-1:17, preferably 1:2667-1:33, preferably 1:2667-1:104, preferably 1:2667-1 :208, preferably 1:2667-1:417, preferably 1:2667-1:833, preferably 1:2667-1:1667, preferably 1:2667-1:2000, preferably 1:2667-1:2333, preferably 1:2333-1:0.3, preferably 1:2333-1:3, preferably 1:2333-1:17, preferably 1:2333-1:33, preferably 1:2333-1:104, preferably 1:2333-1:208, preferably 1:2333-1:417, preferably 1:2333-1:833, preferably 1:2333-1:1667, preferably 1:2333-1:2000, preferably 1:2000-1:0.3 , preferably 1:2000-1:3, preferably 1:2000-1:17, preferably 1:2000-1:33, preferably 1:2000-1:104, preferably 1:2000-1:208, preferably 1:2000-1:417, preferably 1:2000-1:833, preferably 1:2000-1:1667, preferably 1:1667-1:0.3, preferably 1:1667-1:3, preferably 1:1667-1:17, preferably 1:1667-1:33, preferably 1:1667-1:104, preferably 1:1667-1:208, preferably 1:1667-1:417, preferably 1:1667-1:833, preferably 1:833-1:0.3, preferably 1:833-1:3, preferably 1:833-1:17, preferably 1:833-1:33, preferably 1:833-1:104, preferably 1:833-1:208, preferably 1:833-1:417, preferably 1:417-1:0.3, preferably 1:417-1:3, preferably 1:417-1:17, preferably 1:417-1:33, preferably 1:417-1:104, preferably 1:417-1:208, preferably 1:208-1:0.3, Preferably 1:208-1:3, preferably 1:208-1:17, preferably 1:208-1:33, preferably 1:208-1:104, preferably 1:104-1:0.3, preferably 1:104-1:3, preferably 1:104-1:17, preferably 1:104-1:33, preferably 1:33-1:0.3, preferably 1:33-1:3, preferably 1:33-1:17, preferably 1:17-1:0.3, preferably 1:17-1:3, preferably 1:3-1:0.3. .

[0012] Furthermore, the molar ratio of venetoclax to β-elemene is 1:3333, 1:3000, 1:2667, 1:2333, 1:2000, 1:1667, 1:833, 1:417, 1:208, 1:104, 1:33, 1:17, 1:3, and 1:0.3.

[0013] The present invention provides a pharmaceutical composition for treating cancer, wherein the active ingredients of the pharmaceutical composition include β-elemene and a second drug, wherein the second drug is selected from pemetrexed disodium, zanubrutinib and venedoc.

[0014] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and pemetrexed disodium.

[0015] Further, the molar ratio of pemetrexed disodium to β-elemene is 1:165-1:82, preferably 1:165-1:41, preferably 1:165-1:30, preferably 1:165-1:20, 1:165-1:10, preferably 1:165-1:5, preferably 1:165-1:3, preferably 1:165-1:2, preferably 1:165-1:1, preferably 1:165-1:0.5, preferably 1:165-1:0.3, preferably 1:165-1:0.1, preferably 1:150-1:20, preferably 1:150-1:30, preferably 1:150-1:41, preferably 1:150 -1:82, preferably 1:140-1:20, preferably 1:140-1:30, preferably 1:140-1:41, preferably 1:140-1:82, preferably 1:120-1:20, preferably 1:120-1:30, preferably 1:120-1:41, preferably 1:120-1:82, preferably 1:100-1:20, preferably 1:100-1:30, preferably 1:100-1:41, preferably 1:100-1:82, preferably 1:82-1:20, preferably 1:82-1:30, preferably 1:82-1:41, preferably 1:41-1:20, preferably 1:41-1:30.

[0016] Further, the molar ratio of pemetrexed disodium to β-elemene is 1:165, 1:160, 1:155, 1:150, 1:145, 1:140, 1:135, 1:130, 1:125, 1:120, 1:115, 1:110, 1:105, 1:100, 1:95, 1:90, 1:85, 1:82, 1:80, 1:75, 1:70, 1:65, 1:60, 1:55, 1:50, 1:45, 1:41, 1:35, 1:30, 1:25, 1:20, 1:15, 1:10, 1:5, 1:3, 1:2, 1:1, 1:0.5, 1:0.3, 1:0.2, and 1:0.1.

[0017] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and zanubrutinib.

[0018] Further, the molar ratio of zanubrutinib to β-elemene is 1:1041666-1:50000, preferably 1:1041666-1:100000, preferably 1:1041666-1:130208, preferably 1:1041666-1:260416, preferably 1:1041666-1:502833, preferably 1:502833-1:50000, preferably 1:502833-1:100000, preferably 1:502833-1:130208, preferably 1:502833-1:260416, preferably 1:260416-1:50000, preferably 1:260416-1:100000, preferably 1:260416-1:130208.

[0019] Furthermore, the molar ratio of zanubrutinib to β-elemene is 1:1041666, 1:502833, 1:260416, 1:130208, 1:100000, and 1:50000.

[0020] Furthermore, the active ingredients of the pharmaceutical composition consist of β-elemene and venetoclax.

[0021] Further, the molar ratio of venetoclax to β-elemene is 1:3333-1:0.3, preferably 1:3333-1:3, preferably 1:3333-1:17, preferably 1:3333-1:33, preferably 1:3333-1:104, preferably 1:3333-1:208, preferably 1:3333-1:417, preferably 1:3333-1:833, preferably 1:3333-1:1667, preferably 1:3333-1:2000, preferably 1:3333-1:2333, preferably 1:3333-1:2667, preferably 1:3333-1:3000, preferably 1:3000-1:0.3, preferably 1:3000-1: 3, preferably 1:3000-1:17, preferably 1:3000-1:33, preferably 1:3000-1:104, preferably 1:3000-1:208, preferably 1:3000-1:417, preferably 1:3000-1:833, preferably 1:3000-1:1667, preferably 1:3000-1:2000, preferably 1:3000-1:2333, preferably 1:3000-1:2667, preferably 1:2667-1:0.3, preferably 1:2667-1:3, preferably 1:2667-1:17, preferably 1:2667-1:33, preferably 1:2667-1:104, preferably 1:2667-1:208, preferably 1:2667-1:417, preferably 1:2667-1:833, preferably 1:2667-1:1667, preferably 1:2667-1:2000, preferably 1:2667-1:2333, preferably 1:2333-1:0.3, preferably 1:2333-1:3, preferably 1:2333-1:17, preferably 1:2333-1:33, preferably 1:2333-1:104, preferably 1:2333-1:208, preferably 1:2333-1:417, preferably 1:2333-1:833, preferably 1:2333-1:1667, preferably 1:2333-1:2000, preferably 1:2000-1:0.3, preferably 1 :2000-1:3, preferably 1:2000-1:17, preferably 1:2000-1:33, preferably 1:2000-1:104, preferably 1:2000-1:208, preferably 1:2000-1:417, preferably 1:2000-1:833, preferably 1:2000-1:1667, preferably 1:1667-1:0.3, preferably 1:1667-1:3, preferably 1:1667-1:17, preferably 1:1667-1:33, preferably 1:1667-1:104, preferably 1:1667-1:208, preferably 1:1667-1:417, preferably 1:1667-1:833, preferably 1:833-1:0.3, preferably 1:833-1:3, preferably 1:833-1:17, preferably 1:833-1:33, preferably 1:833-1:104, preferably 1:833-1:208, preferably 1:833-1:417, preferably 1:417-1:0.3, preferably 1:417-1:3, preferably 1:417-1:17, preferably 1:417-1:33, preferably 1:417-1:104, preferably 1:417-1:208, preferably 1:208-1:0.3, Preferably 1:208-1:3, preferably 1:208-1:17, preferably 1:208-1:33, preferably 1:208-1:104, preferably 1:104-1:0.3, preferably 1:104-1:3, preferably 1:104-1:17, preferably 1:104-1:33, preferably 1:33-1:0.3, preferably 1:33-1:3, preferably 1:33-1:17, preferably 1:17-1:0.3, preferably 1:17-1:3, preferably 1:3-1:0.3. .

[0022] Furthermore, the molar ratio of venetoclax to β-elemene is 1:3333, 1:3000, 1:2667, 1:2333, 1:2000, 1:1667, 1:833, 1:417, 1:208, 1:104, 1:33, 1:17, 1:3, and 1:0.3.

[0023] Further, the present invention provides a pharmaceutical composition for treating cancer comprising the above-mentioned drug, wherein the pharmaceutical composition comprises pharmaceutically acceptable pharmaceutical excipients, including but not limited to injection oil, carrier, filler, disintegrant, binder, lyophilization protectant, pH regulator, preservative, antioxidant, wetting agent, etc. The pharmaceutical composition can be prepared into a preparation, and the preparation can be one or more of tablets, capsules, pills, mixtures, gels, ointments, granules, powders, pastes, granules, pills, oral liquids, drop pills, injections or injections, or any other dosage form.

[0024] Furthermore, the present invention provides a use of the above composition or medicine in preparing a medicine for treating cancer.

[0025] Further, the cancer is leukemia (including promyelocytic leukemia, etc.), lung cancer, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, malignant melanoma, B lymphocyte tumor (including chronic lymphocytic leukemia / small lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, follicular lymphoma, non-germinal center subtype diffuse large B-cell lymphoma, etc.), colorectal cancer, malignant pleural mesothelioma, pancreatic cancer, head and neck cancer, gastric cancer, bladder cancer, bone cancer, esophageal cancer, brain tumor, liver cancer, cervical cancer, cancerous chest, ascites, preferably the cancer is lung cancer, breast cancer, ovarian cancer, B lymphocyte tumor, leukemia, more preferably lung cancer, B lymphocyte tumor, leukemia.

[0026] Specific implementation examples

[0027] The technical solution of the present invention is further described in detail below in conjunction with the specification and specific implementation examples, but the implementation of the present invention is not limited thereto. The equivalent replacement, combination, improvement or modification of the technical solution of the present invention made by those skilled in the art based on the description of the present invention should be included in the protection scope of the present invention.

[0028] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0029] The following examples are calculated in the following manner:

[0030] 1) Calculation of tumor growth inhibition rate

[0031] Tumor cell growth inhibition rate IR (%) = (1-(RLU compound-RLU blank control) / (RLU solvent control-RLU blank control))*100%

[0032] 2) Determination of the effect of dual-drug combination therapy:

[0033] The determination was made by the Jin Zhengjun q value method (see non-patent literature: Dai Tijun. Quantitative analysis of combined medication [J]. Chinese Pharmacological Bulletin, 1998 (5): 479-480.). q = P (A + B) / (PA + PB - PA × PB). In the formula, PA, PB and P (A + B) are the inhibition rates of the β-elemene drug group, the second drug group and the two-drug combination group, respectively. q < 1 indicates that the two drugs produce an antagonistic effect after combination; q > 1 indicates that the two drugs produce a synergistic effect after combination; q = 1 indicates that the two drugs produce an additive effect after combination.

[0034] Example 1

[0035] Beta-elemene and pemetrexed disodium are divided into:

[0036] Group 1: 300uM β-elemene, Group 2: 150uM β-elemene, Group 3: 75uM β-elemene, Group 4: 37.5uM β-elemene, Group 5: 1.82uM pemetrexed disodium;

[0037] Group VI: 300uM β-elemene + 1.82uM pemetrexed disodium, Group VII: 150uM β-elemene + 1.82uM pemetrexed disodium, Group VIII: 75uM β-elemene + 1.82uM pemetrexed disodium, Group IX: 37.5uM β-elemene + 1.82uM pemetrexed disodium.

[0038] The above groups all used 0.5% DMSO as the solvent.

[0039] Cell culture: A549 was inoculated in a sterile culture bottle, and an appropriate amount of F-12K + 10% FBS culture medium was added. The cells were cultured in an incubator at 37°C, 5% CO2 and saturated humidity. The cells grew as a monolayer and were passaged once every 2 to 3 days. During passage, the cultured cells were digested with 0.25% trypsin + 0.02% EDTA for 2 to 4 minutes, and the culture medium was pipetted and blown to make the cells into a cell suspension, and then inoculated at the required concentration. Take the A549 cells in the logarithmic growth phase, make a single cell suspension according to the passage method, count, and adjust the cell concentration to: 4.45*10^4 / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were taken as blanks for zero adjustment. After the culture plate was placed in a 37°C, 5% CO2 incubator for 12 hours, 10 μL (5 μL of different concentrations of β-elemene + 5 μL of pemetrexed disodium) was added to groups 6-9, and 5 μL of different concentrations of β-elemene + 5 μL of 5% DMSO medium was added to groups 1-4. Group 5 was added with 5 μL of 36.4uM pemetrexed disodium + 5 μL of 5% DMSO medium, and the vehicle control was added with 10 μL of 5% DMSO medium. Each group was set up with duplicate wells, and after 72 hours of culture, 50 μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0040] The experimental results are shown in Table 1:

[0041] Table 1

[0042] Q-value Molar ratio (pemetrexed disodium: β-elemene) Group 6 0.98 1:165 Group 7 1.32 1:82 Group 8 1.10 1:41 Group 9 0.87 1:20

[0043] Example 2

[0044] β-elemene and zanubrutinib were divided into: Group 1: 250uM β-elemene, Group 2: 125uM β-elemene, Group 3: 62.5uM β-elemene, Group 4: 31.25uM β-elemene, Group 5: 24uM β-elemene, Group 6: 12uM β-elemene, Group 7: 0.24nM zanubrutinib.

[0045] Group 8: 250uM β-elemene + 0.24nM zanubrutinib, Group 9: 125uM β-elemene + 0.24nM zanubrutinib, Group 10: 62.5uM β-elemene + 0.24nM zanubrutinib, Group 11: 31.25uM β-elemene + 0.24nM zanubrutinib, Group 12: 24uM β-elemene + 0.24nM zanubrutinib, Group 13: 12uM β-elemene + 0.24nM zanubrutinib.

[0046] The above groups all used 0.5% DMSO as the solvent.

[0047] Cell culture: Human lymphoma TMD8 cells were inoculated into sterile culture bottles, and an appropriate amount of RPMI1640 + 10% FBS culture medium was added, and cultured in an incubator at 37°C, 5% CO2 and saturated humidity. The cells grew as a monolayer adherent to the wall and were passaged once every 2 to 3 days. During passage, the cultured cells were digested with 0.25% trypsin + 0.02% EDTA for 2 to 4 minutes, and the culture medium was pipetted and blown to make the cells into a cell suspension, and then inoculated according to the required concentration.

[0048] Methods: TMD8 cells in the logarithmic growth phase were taken, and single-cell suspension was made according to the passaging method. The cells were counted and the cell concentration was adjusted to 8.89*10^4 cells / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90 μL of cell suspension was added to each well. The wells without cell culture medium were used as blank zeros. After the culture plate was placed in a 37°C, 5% CO2 incubator for 12 hours, 10 μL (5 μL of different concentrations of β-elemene and 5 μL of zabutinib) was added to groups 8-13, 5 μL of different concentrations of β-elemene + 5 μL of 5% DMSO culture medium was added to groups 1-6, and 5 μL of zabutinib + 5 μL of 5% DMSO culture medium was added to group 7. The solvent control was to add 10 μL of 5% DMSO culture medium. Each group was set up with duplicate wells, and after 72 hours of culture, 50 μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, 300 rpm / min, 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0049] The experimental results are shown in Table 2:

[0050] Table 2

[0051] Q-value Molar ratio (zanubrutinib: β-elemene) Group 8 1.02 1:1041666 Group 9 1.01 1:520833 Group 10 3.50 1:260416 Group 11 1.74 1:130208 Group 12 0.89 1:100000 Group 13 0.91 1:50000

[0052] Example 3

[0053] Beta-elemene and venetoclax are divided into:

[0054] Group 1: 500uM β-elemene, Group 2: 125uM β-elemene, Group 3: 31.25uM β-elemene, Group 4: 0.3uM venetoclax;

[0055] Group five: 500uM β-elemene + 0.3uM venetoclax, Group six: 125uM β-elemene + 0.3uM venetoclax, Group seven: 31.25uM β-elemene + 0.3uM venetoclax.

[0056] The above groups all used 0.5% DMSO as the solvent.

[0057] Cell culture: HL60 was inoculated in a sterile culture bottle, and an appropriate amount of IMDM + 20% FBS culture medium was added. The cells were cultured in an incubator at 37°C, 5% CO2 and saturated humidity. The cells grew as a monolayer and were passaged once every 2 to 3 days. During passage, the cultured cells were digested with 0.25% trypsin + 0.02% EDTA for 2 to 4 minutes, and the culture medium was pipetted and blown to make the cells into a cell suspension, and then inoculated according to the required concentration. Take the HL60 cells in the logarithmic growth period, make a single cell suspension according to the passage method, count, and adjust the cell concentration to: 5.56*10^4 / mL. The above cell suspension was inoculated in a 96-well cell culture plate, and 90μL of cell suspension was added to each well. The wells without cell culture medium were taken as blanks for zero adjustment. After the culture plate was placed in a 37°C, 5% CO2 incubator for 12 hours, 10 μL (5 μL of different concentrations of β-elemene + 5 μL of 6uM venetoclax) was added to groups 5-7, 5 μL of different concentrations of β-elemene + 5 μL of 5% DMSO medium was added to groups 1-3, 5 μL of 6uM venetoclax + 5 μL of 5% DMSO medium was added to group 4, and 10 μL of 5% DMSO medium was added to the vehicle control. Each group was set up with duplicate wells, and after 72 hours of culture, 50 μL of CellTiter-Glo was added to each well. TM Reagent, on an oscillator, protected from light, at 300 rpm / min for 3 min, let stand for 10 min, and then use an automatic microplate reader to measure the fluorescence signal value of each well.

[0058] The experimental results are shown in Table 3:

[0059] Table 3

[0060] Q-value Molar ratio (Venetoclax:β-elemene) Group 5 1.12 1:1667 Group 6 1.12 1:417 Group 7 1.07 1:104

Claims

1. A combined drug for treating cancer, characterized in that The combination drug comprises β-elemene and a second drug, and the combination drug is a single compound preparation or a combination of two separate preparations. Preferably, the second drug is selected from pemetrexed disodium, zanubrutinib and venedoc.

2. The combined drug according to claim 1, characterized in that The second drug is selected from pemetrexed disodium, and the molar ratio of pemetrexed disodium to β-elemene is 1:165-1:20, preferably 1:82-1:

41.

3. The combined drug according to claim 1, characterized in that The second drug is selected from zanubrutinib, and the molar ratio of zanubrutinib to β-elemene is 1:1041666-1:50000, preferably 1:260416-1:130208.

4. The combined drug according to claim 1, characterized in that The second drug is selected from venedoc, and the molar ratio of venedoc to β-elemene is 1:3333-1:0.3, preferably 1:1667-1:

104.

5. A pharmaceutical composition for treating cancer, characterized in that The active ingredients of the pharmaceutical composition include β-elemene and a second drug, preferably the second drug is selected from pemetrexed disodium, zanubrutinib, and venedoc. Preferably, the active ingredients of the pharmaceutical composition consist of β-elemene and pemetrexed disodium, or β-elemene and zanubrutinib, or β-elemene and venedoc. Preferably, the pharmaceutical composition contains pharmaceutically acceptable excipients.

6. The pharmaceutical composition according to claim 5, characterized in that The molar ratio of pemetrexed disodium to β-elemene is 1:165-1:20, preferably 1:82-1:

41.

7. The pharmaceutical composition according to claim 5, characterized in that The molar ratio of zanubrutinib to β-elemene is 1:1041666-1:50000, preferably 1:260416-1:130208.

8. The pharmaceutical composition according to claim 5, characterized in that The molar ratio of zanubrutinib to β-elemene is 1:3333-1:0.3, preferably 1:1667-1:

104.

9. Use of the composition or drug according to any one of claims 1 to 8 in the preparation of a combined drug for treating cancer, wherein the cancer is preferably leukemia, lung cancer, breast cancer, ovarian cancer, small cell lung cancer, non-small cell lung cancer, malignant melanoma, B lymphocyte tumor, colorectal cancer, malignant pleural mesothelioma, pancreatic cancer, head and neck cancer, gastric cancer, bladder cancer, bone cancer, esophageal cancer, brain tumor, liver cancer, cervical cancer, cancerous chest, ascites, and preferably the cancer is lung cancer, breast cancer, ovarian cancer, B lymphocyte tumor, leukemia, and more preferably lung cancer, B lymphocyte tumor, leukemia.

Citation Information

Cited By

  • Drug containing elemene and kinase inhibitor

    WO2025149017A1